Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Operating Margin (2022 - 2025)

Historic Operating Margin for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to 103.5%.

  • Atara Biotherapeutics' Operating Margin fell 493700.0% to 103.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.26%, marking a year-over-year increase of 1478800.0%. This contributed to the annual value of 64.71% for FY2024, which is 31547700.0% up from last year.
  • As of Q3 2025, Atara Biotherapeutics' Operating Margin stood at 103.5%, which was down 493700.0% from 18.19% recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Operating Margin ranged from a high of 39.53% in Q1 2025 and a low of 34180.54% during Q4 2022
  • Moreover, its 4-year median value for Operating Margin was 114.22% (2024), whereas its average is 3727.28%.
  • Examining YoY changes over the last 5 years, Atara Biotherapeutics' Operating Margin showed a top increase of 327703400bps in 2023 and a maximum decrease of -73999800bps in 2023.
  • Over the past 4 years, Atara Biotherapeutics' Operating Margin (Quarter) stood at 34180.54% in 2022, then surged by 96bps to 1410.21% in 2023, then skyrocketed by 97bps to 37.26% in 2024, then tumbled by -178bps to 103.5% in 2025.
  • Its last three reported values are 103.5% in Q3 2025, 18.19% for Q2 2025, and 39.53% during Q1 2025.